title: Dosage adjustment and clinical outcomes of long-term use of high-dose tobramycin in adult cystic fibrosis patients.
abstract: A two-phase study was undertaken designed to investigate the impact of computer-aided drug monitoring on tobramycin concentrations and clinical outcomes in adult patients with cystic fibrosis. In phase one, a baseline (historical control) study of drug use patterns was performed. During the second phase, patients admitted for intravenous treatment with tobramycin for acute exacerbations of pseudomonal pulmonary infections were randomly allocated to one of two schedules. Group A patients had tobramycin dosage regimens decided by clinicians based on pre-existing protocols using serum tobramycin assay data determined three times weekly. Group B patients had dosage regimens determined by a computerized pharmacokinetic predictive program using both population-based pharmacokinetic parameter estimation and fitting of serum concentration-time data using Bayesian regression. The agreed therapeutic target was a peak serum tobramycin concentration of 8-10 mg/L and a trough concentration of 1-2 mg/L. There was a major difference between the two groups comparing the number of paired trough and peak concentrations within the target concentration ranges (group A-14%; group B-34.7%, chi 2 test, P less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Clinical Pharmacology, Alfred Hospital, Prahran, Victoria, Australia.
authors.forename: S C
authors.initials: SC
authors.lastname: Li
authors.forename: G
authors.initials: G
authors.lastname: Bowes
authors.forename: L L
authors.initials: LL
authors.lastname: Ioannides-Demos
authors.forename: W J
authors.initials: WJ
authors.lastname: Spicer
authors.forename: R E
authors.initials: RE
authors.lastname: Hooper
authors.forename: D W
authors.initials: DW
authors.lastname: Spelman
authors.forename: N
authors.initials: N
authors.lastname: Tong
authors.forename: A J
authors.initials: AJ
authors.lastname: McLean
mesh_terms: D000328:Adult; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D001499:Bayes Theorem; D003550:Cystic Fibrosis / Q000150:complications*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007674:Kidney Diseases / Q000139:chemically induced; D008297:Male; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000401:mortality; D012984:Software; D014031:Tobramycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D014031:Tobramycin